Form D · Biotechnology
TiGenix NV
Leuven, C9 · CIK 0001581987
Offering snapshot reported Jan 9, 2018 · SEC filing
- Reported sold
- $25.9K Offering amount: $195K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 16, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 9, 2018 | Initial | $25,902 | No comparison | 2 | SEC filing |
| Jul 24, 2013 | Initial | $8,540,220 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b, 4a5
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-302735
Source: Form D, filed Jan 9, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| June Almenoff | Director |
| Eduardo Bravo | Director, Executive |
| Eduardo Bravo Fernandez De Araoz | Director, Executive |
| Wilfried Dalemans | Executive |
| Claudia D'augusta | Executive |
| Willy Duron | Director |
| Russell Greig | Director |
| Maria Dolores Pascual Martinez | Executive |
| Marie Paule Richard | Executive |
| Guido Schopen | Executive |
| Jean Stephenne | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Romeinse Straat 12 Box 2, 3001
Leuven, C9, 3001
Leuven, C9, 3001